Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Recurrence 1 Meningeal Neoplasms 1 Inhibition, Psychological 1 Hereditary Sensory and Autonomic Neuropathies 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 23 venetoclax 17 Dexamethasone 16 pembrolizumab 15 fludarabine 15 Cytarabine 13 pomalidomide 8 Rituximab 8 Gemcitabine 8 Carboplatin 8 Azacitidine 8 glofitamab 7 fludarabine phosphate 7 Lenalidomide 7 selinexor 6 Paclitaxel 6 Injections 6 Immunotherapy, Adoptive 6 Granulocyte Colony-Stimulating Factor 6 Cisplatin 6 daratumumab 5 Temozolomide 5 Bevacizumab 5 zanubrutinib 4 ruxolitinib 4 Surgical Procedures, Operative 4 Oxaliplatin 4 Nivolumab 4 Drug Therapy 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × AZD1390 × Clear all

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡